Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the androgenicity of progestins used in hormonal contraceptives and its potential impact on female pattern hair loss, but reports no new clinical findings.

This review evaluates previous studies on androgen-progestin combinations for male contraception, concluding that long-acting injectable formulations appear promising due to their effectiveness and minimal short-term adverse effects.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This review discusses the physiological basis, history, and current development of male hormonal contraception, highlighting its potential risks and benefits, but reports no new research findings.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This meta-analysis reported that dienogest and combined oral contraceptives had comparable efficacy and tolerability for endometriosis treatment, with therapeutic choice suggested to be based on patient preference and clinical history.

In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.

In this study, COC treatment led to greater improvements in sex hormone, endocrine factor, and metabolic levels among PCOS patients compared to those who did not receive the treatment.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.

This review discusses the effectiveness and mechanisms of combined oral contraceptives in treating acne vulgaris but reports no new clinical results; the authors highlight their antiandrogenic effects for managing acne and related endocrine disorders.

This study assessed the impact of hormonal contraceptives on liver function in 46 women aged 25-45 and found that contraceptive users, particularly those using combined oral contraceptives, had significantly higher liver enzyme levels compared to non-users, suggesting potential adverse effects that warrant further investigation.

This source discusses the noncontraceptive uses of combined oral contraceptives in adolescents, noting that a significant portion use them for issues like menstrual symptoms, but it reports no new study results.

This article reviews the effects of combined oral contraceptives on skin conditions and suggests prescribing guidelines for women with acne, as it reports no new clinical results.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This review discusses various cutaneous side effects potentially linked to oral contraceptive use but provides no new clinical results, emphasizing the need for more evidence in certain associations.

In this animal study, rats given high doses of ethynylestradiol showed dose-related estrogenic effects, delayed tumor onset in females, and no overall increase in tumor incidence compared to controls.

This study in female beagle dogs found that long-term exposure to oral contraceptive steroids resulted in significant reproductive and mammary gland changes, with the relevance to human tumor risk remaining uncertain.

This study found that feeding norethindrone acetate to albino rats over two years caused various dose-related health effects, such as growth retardation and liver changes, but did not increase overall tumor incidence.

In this study, oral contraceptives containing desogestrel or cyproteron acetate effectively treated hyperandrogenism in women with polycystic ovary syndrome, while ovarian electrocautery is recommended for those with concurrent infertility.

This study found that self-reported use of finasteride or oral contraceptives did not reduce the incidence of renal cancer in participants of the PCLO trial.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

This review discusses potential drug interactions between herbal medicines and oral contraceptives, reporting no new research results but highlighting the risk these interactions pose to contraceptive effectiveness.

This study found that adverse effects from hormonal contraception were more common and severe with progestin-only injections compared to estradiol levonorgestrel combination pills.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.